200 related articles for article (PubMed ID: 11259564)
21. Type and location of fluorescent probes incorporated into the potent mu-opioid peptide [Dmt]DALDA affect potency, receptor selectivity and intrinsic efficacy.
Schiller PW; Berezowska I; Weltrowska G; Chen H; Lemieux C; Chung NN
J Pept Res; 2005 Jun; 65(6):556-63. PubMed ID: 15885115
[TBL] [Abstract][Full Text] [Related]
22. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
23. Enkephalin derivative, cyclo[Nepsilon,Nbeta-carbonyl-D-Lys2, Dap5] enkephalinamide (cUENK6), induces a highly potent antinociception in rats.
Kotlinska J; Bochenski M; Lagowska-Lenard M; Gibula-Bruzda E; Witkowska E; Izdebski J
Neuropeptides; 2009 Jun; 43(3):221-8. PubMed ID: 19376576
[TBL] [Abstract][Full Text] [Related]
24. Dansylated analogues of the opioid peptide [Dmt1]DALDA: in vitro activity profiles and fluorescence parameters.
Berezowska I; Lemieux C; Chung NN; Zelent B; Schiller PW
Acta Biochim Pol; 2004; 51(1):107-13. PubMed ID: 15094830
[TBL] [Abstract][Full Text] [Related]
25. The bifunctional μ opioid agonist/antioxidant [Dmt(1)]DALDA is a superior analgesic in an animal model of complex regional pain syndrome-type i.
Schiller PW; Nguyen TM; Saray A; Poon AW; Laferrière A; Coderre TJ
ACS Chem Neurosci; 2015 Nov; 6(11):1789-93. PubMed ID: 26352668
[TBL] [Abstract][Full Text] [Related]
26. Opioid peptide-derived analgesics.
Schiller PW
AAPS J; 2005 Oct; 7(3):E560-5. PubMed ID: 16353933
[TBL] [Abstract][Full Text] [Related]
27. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and in vitro opioid activity profiles of DALDA analogues.
Schiller PW; Nguyen TM; Berezowska I; Dupuis S; Weltrowska G; Chung NN; Lemieux C
Eur J Med Chem; 2000 Oct; 35(10):895-901. PubMed ID: 11121615
[TBL] [Abstract][Full Text] [Related]
29. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
[TBL] [Abstract][Full Text] [Related]
30. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens.
Al-Khrasani M; Spetea M; Friedmann T; Riba P; Király K; Schmidhammer H; Furst S
Brain Res Bull; 2007 Oct; 74(5):369-75. PubMed ID: 17845912
[TBL] [Abstract][Full Text] [Related]
31. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.
Vanderah TW; Schteingart CD; Trojnar J; Junien JL; Lai J; Riviere PJ
J Pharmacol Exp Ther; 2004 Jul; 310(1):326-33. PubMed ID: 14993260
[TBL] [Abstract][Full Text] [Related]
32. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
33. Quantification of [Dmt1]DALDA in ovine plasma by on-line liquid chromatography/quadrupole time-of-flight mass spectrometry.
Wan H; Desiderio DM
Rapid Commun Mass Spectrom; 2003; 17(6):538-46. PubMed ID: 12621615
[TBL] [Abstract][Full Text] [Related]
34. Differential inhibitory effects of mu-opioids on substance P- and capsaicin-induced nociceptive behavior in mice.
Watanabe H; Nakayama D; Yuhki M; Sawai T; Sakurada W; Katsuyama S; Hayashi T; Watanabe C; Mizoguchi H; Fujimura T; Sakurada T; Sakurada S
Peptides; 2006 Apr; 27(4):760-8. PubMed ID: 16226344
[TBL] [Abstract][Full Text] [Related]
35. Highly potent fluorescent analogues of the opioid peptide [Dmt1] DALDA.
Berezowska I; Chung NN; Lemieux C; Zelent B; Szeto HH; Schiller PW
Peptides; 2003 Aug; 24(8):1195-200. PubMed ID: 14612191
[TBL] [Abstract][Full Text] [Related]
36. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists.
Sluka KA; Rohlwing JJ; Bussey RA; Eikenberry SA; Wilken JM
J Pharmacol Exp Ther; 2002 Sep; 302(3):1146-50. PubMed ID: 12183674
[TBL] [Abstract][Full Text] [Related]
37. Dermorphin analog Tyr-D-Arg2-Phe-sarcosine-induced opioid analgesia and respiratory stimulation: the role of mu 1-receptors?
Paakkari P; Paakkari I; Vonhof S; Feuerstein G; Sirén AL
J Pharmacol Exp Ther; 1993 Aug; 266(2):544-50. PubMed ID: 8394909
[TBL] [Abstract][Full Text] [Related]
38. Opioid activities of D-Arg2-substituted tetrapeptides.
Sato T; Sakurada S; Sakurada T; Furuta S; Chaki K; Kisara K; Sasaki Y; Suzuki K
J Pharmacol Exp Ther; 1987 Aug; 242(2):654-9. PubMed ID: 3612556
[TBL] [Abstract][Full Text] [Related]
39. In vivo disposition of dermorphin analog (DALDA) in nonpregnant and pregnant sheep.
Szeto HH; Clapp JF; Desiderio DM; Schiller PW; Grigoriants OO; Soong Y; Wu D; Olariu N; Tseng JL; Becklin R
J Pharmacol Exp Ther; 1998 Jan; 284(1):61-5. PubMed ID: 9435161
[TBL] [Abstract][Full Text] [Related]
40. Fluorescent dyes alter intracellular targeting and function of cell-penetrating tetrapeptides.
Szeto HH; Schiller PW; Zhao K; Luo G
FASEB J; 2005 Jan; 19(1):118-20. PubMed ID: 15489247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
